Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: A single center analysis

Journal of Medical Virology

Volumn 80, Issue 5, 2008, Pages 747-753

  Lapadula, Giuseppe ^a   Izzo, Ilaria ^a   Gargiulo, Franco ^a   Paraninfo, Giuseppe ^a   Castelnuovo, Filippo ^a   Quiros Roldan, Eugenia ^a   Cologni, Giuliana ^a   Ceresoli, Francesca ^a   Manca, Nino ^a   Carosi, Giampiero ^a   Torti, Carlo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antiretroviral therapy; HIV; Na ve; Resistance mutations

Indexed keywords

3' O BENZYLTRIFLURIDINE; ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; ALGORITHM; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ITALY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; RISK FACTOR;

ADULT; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL;

BRESCIA; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41849144119     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21139     Document Type: Article

References (29)

1. Agwale SM, Zeh C, Paxinos E, Odama L, Pienazek D, Wambebe C, Kalish ML, Ziermann R. 2006. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 22:22-26.
2. Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 80:10794-10801.
3. Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L. 2006. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: Effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 11:173-178.
4. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. 2007. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59:517-524.
5. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M. 2005. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. Br Med J 331:1368.
6. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V. 2001. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 65:445-4448.
7. Eshleman SH, Husnik M, Hudelson S, Donnell D, Huang Y, Huang W, Hart S, Jackson B, Coates T, Chesney M, Koblin B. 2007. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 21:1165-1174.
8. Geretti AM. 2007. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 20:22-32.
9. Harrigan PR, Mo T, Wynhoven B, Hirsch J, Brumme Z, McKenna P, Pattery T, Vingerhoets J, Bacheler LT. 2005. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 19:549-554.
10. Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14:125-130.
11. Little SJ. 2000. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther 5:33-40.
12. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385-394.
13. Lohse N, Obel N, Kronborg G, Jorgensen LB, Pedersen C, Larsen CS, Kvinesdal B, Sorensen HT, Gerstoft J. 2006. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 11:591-600.
14. Maia Teixeira SL, Bastos FI, Hacker MA, Guimaraes ML, Morgado MG. 2006. Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol 78:764-769.
15. Oette M, Kaiser R, Daumer M, Petch R, Fatkenheuer G, Carls H, Rockstroh JK, Schmaloer D, Stechel J, Feldt T, Pfister H, Haussinger D. 2006. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 41:573-581.
16. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, Knechten H, Schmutz G, Hower M, Emmelkamp J, Pfister H, Haussinger D. 2007. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 60:843-848.
17. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215-223.
18. Sighinolfi L, Torti C, Zeni C, Ghinelli F, Suter F, Maggiolo F, Antinori A, Antonucci G, Castelnuovo F, Ladisa N, Migliorino M, Novati S, De Luca A, Lo Caputo S, Paraninfo G, Tinelli C, Carosi G. 2007. Evolution of antiretroviral prescription and response over a period of 8 years: An Italian Multicenter observational prospective cohort study. Infection, (in press).
19. Smith DM, Wong JK, Shao H, Hightower GK, Mai SH, Moreno JM, Ignacio CC, Frost SD, Richman DD, Little SJ. 2007. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: Implications for secondary transmission. J Infect Dis 196:356-360.
20. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M. 2005. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 366:378-384.
21. Tee KK, Kamarulzaman A, Ng KP. 2006. Short communication: Low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses 22:121-124.
22. Torti C, Bono L, Gargiulo F, Uccelli MC, Quiros-Roldan E, Patroni A, Paraninfo G, Tirelli V, Manca N, De Francesco MA, Perandin F, Carosi G. 2004. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals. Clin Microbiol Infect 10:826-830.
23. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study and UK Register of HIV Seroconverters. 2007. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 21:1035-1039.
24. Vandamme AM, Sonnerborg A, it-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. 2004. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 9:829-848.
25. Vergne L, Diagbouga S, Kouanfack C, Aghokeng A, Butel C, Laurent C, Noumssi N, Tardy M, Sawadogo A, Drabo J, Hien H, Zekeng L, Delaporte E, Peeters M. 2006. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 11:575-579.
26. Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N, Wilson CM. 2006. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 194:1505-1509.
27. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C. 2004a. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18:227-235.
28. Violin M, Velleca R, Cozzi-Lepri A, Riva C, Grossi PA, Carnevale G, Rizzardini G, Petrelli E, Perno CF, d'Arminio Monforte A, Balotta C. 2004b. Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001. J Acquir Immune Defic Syndr 36:761-764.
29. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192:958-966.